Distribution of HHV-8 (KSHV) IgG antibody in sera from MGUS, MM, KS, and healthy donors detected by whole-virus lysate ELISA and by IFA to latent antigens
| Serum ID . | ELISA . | Antibody to latent antigens . |
|---|---|---|
| No. positive/no. tested . | No. positive/no. tested . | |
| MGUS | 26/362 (7.1%) | 3/95 (3.2%) |
| MM | 6/110 (5.4%) | 3/65 (4.6%) |
| Classic KS (positive control) | 20/20 (100.0%) | 18/20 (90.0%) |
| Healthy donors (adult) | 6/102 (5.9%) | 2/50 (4.0%) |
| Serum ID . | ELISA . | Antibody to latent antigens . |
|---|---|---|
| No. positive/no. tested . | No. positive/no. tested . | |
| MGUS | 26/362 (7.1%) | 3/95 (3.2%) |
| MM | 6/110 (5.4%) | 3/65 (4.6%) |
| Classic KS (positive control) | 20/20 (100.0%) | 18/20 (90.0%) |
| Healthy donors (adult) | 6/102 (5.9%) | 2/50 (4.0%) |
ELISA and IFA to lytic antigens were performed according to the assay of Chatlynne et al,22 using the HHV-8 ELISA and IFA kits from Advanced Biotechnologies Inc. For ELISA, the sera were diluted at 1:100, and for IFA, the sera were diluted at 1:40. IFA to lytic antigens was used to confirm the ELISA-positive sera for antibody to HHV-8. Antibody to latent antigens was tested by IFA using a 1:100 dilution according to the procedure of Simpson et al.23